Pacira Pharmaceuticals buy Needham & Company LLC
Start price
09.04.24
/
50%
€25.80
Target price
09.04.25
€41.35
Performance (%)
-6.98%
Price
26.04.24
€24.00
Summary
This prediction is currently active. With a performance of -6.98%, the BUY prediction for Pacira Pharmaceuticals by Needham___Company_LL is down slightly. This prediction currently runs until 09.04.25. The prediction end date can be changed by Needham___Company_LL at any time. Needham___Company_LL has 50% into this predictionPerformance without dividends (%)
| Name | 1w |
|---|---|
| Pacira Pharmaceuticals | 0.840% |
| iShares Core DAX® | 0.961% |
| iShares Nasdaq 100 | 2.626% |
| iShares Nikkei 225® | 0.217% |
| iShares S&P 500 | 1.540% |
Comments by Needham___Company_LL for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Needham___Company_LL for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€26.80
01.03.24
01.03.24
€41.61
01.03.25
01.03.25
-10.45%
26.04.24
26.04.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€33.40
03.08.23
03.08.23
€47.53
03.08.24
03.08.24
-28.14%
26.04.24
26.04.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€41.00
20.04.23
20.04.23
€54.71
20.04.24
20.04.24
-40.98%
21.04.24
21.04.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€40.40
28.02.23
28.02.23
€56.63
28.02.24
28.02.24
-32.18%
29.02.24
29.02.24